Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.


Last reviewed on RxList: 5/17/2019
Sorilux Side Effects Center

Last reviewed on RxList 5/17/2019

Sorilux (calcipotriene) Foam, 0.005% is a manmade form of vitamin D3 used for the topical treatment of plaque psoriasis in patients aged 18 years and older. Common side effects of Sorilux Foam include:

  • skin redness
  • irritation
  • swelling
  • rash, and
  • itching in the treated area

Apply a thin layer dose of Sorilux Foam twice daily to the affected areas and rub in gently and completely. Sorilux may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Sorilux should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Our Sorilux (calcipotriene) Foam, 0.005% Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Psoriasis causes the top layer of skin cells to become inflamed and grow too quickly and flake off. See Answer
Sorilux Professional Information


Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

SORILUX Foam was studied in four vehicle-controlled trials. A total of 1094 adult subjects with plaque psoriasis, including 654 exposed to SORILUX Foam, were treated twice daily for 8 weeks. Adverse reactions reported in ≥1% of subjects treated with SORILUX Foam and at a higher incidence than subjects treated with vehicle were application site erythema (2%) and application site pain (3%). The incidence of these adverse reactions was similar between the body and scalp.

In an open-label study, 19 pediatric subjects age 12 to less than 17 years applied SORILUX Foam twice daily for 14 days and once on Day 15. Adverse reactions included application site pain, application site pruritus and pruritus [see CLINICAL PHARMACOLOGY and Pediatric Use].

Read the entire FDA prescribing information for Sorilux (Calcipotriene Foam)


Types of Psoriasis: Medical Pictures and Treatments See Slideshow
Related Resources for Sorilux

Related Drugs

© Sorilux Patient Information is supplied by Cerner Multum, Inc. and Sorilux Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors